Screening centres in academic institutions and non-profit organisations have, over the past decade, become an established mechanism to exploit novel targets and neglected diseases and to identify chemical probes. Where centres have a disease focus, their main expertise resides in cancer and phenotypic screens, with screening experience greatest for kinases, phenotypic approaches and protein-protein interactions.
Many disapprove of science faculty at American universities procuring corporate ventures that support research, instead of primarily functioning as an instructor, mentor and basic researcher. This perception is most evident surrounding biomedical research at public universities. In addition, some object that corporate-funded projects involve student research. In contrast, harmony and accord with companies has been a staple at institutions with medical, engineering or technology within their venerable names.
Many academic HTS centres, faced with the high costs of drug discovery and decreasing federal funding, are struggling to survive. Just as with any small business, a sound business plan is critical for achieving and maintaining self sustainability.